High pulmonary vascular resistance (PVR) is associated with worse mortality rates among people with pulmonary hypertension (PH), and the bottom threshold for what constitutes “elevated” PVR is lower than previously thought, a new study suggests. “The findings of this study cast the clinical profile of patients who have PH and…
Preterm babies with the lung condition bronchopulmonary dysplasia (BPD) — a risk factor for the development of pulmonary hypertension (PH) — have lower levels of the anti-aging-associated protein Klotho, a study shows. The results support the potential for Klotho as a biomarker for BPD. Moreover, early Klotho…
A case report found a patient’s pulmonary arterial hypertension (PAH) was caused by an undiagnosed case of the autoimmune disorder systemic sclerosis (SSc), highlighting the need for early and thorough diagnostic workups, researchers say. The 77-year-old woman’s PAH was also worsened by other conditions, including lung…
People with pulmonary arterial hypertension (PAH) who are treated at specialty care centers have better survival chances and a lower likelihood of hospitalization, a study reports. These findings support referring PAH patients to specialty care centers for treatment, where factors like more careful disease monitoring might be decisive. The…
Paula Menezes has been awarded a $50,000 PHenomenal Impact Fund for Global PH Research grant to identify challenges faced by pulmonary hypertension (PH) patients and caregivers in parts of Latin America. Menezes’ project proposal is titled “Living with Pulmonary Hypertension in Latin America: A Patient’s…
When used alone or in combination with other therapies, Opsumit (macitentan) can lower the mortality risk in patients with pulmonary arterial hypertension (PAH), a study found. The study, “Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice:…
Pregnant women with pulmonary arterial hypertension (PAH) should seek specialist care before giving birth and for months afterward, due to the risk of severe maternal complications and high rates of premature births, according to a study in China. The study, “Pregnancy outcomes in patients with pulmonary…
A protein called interleukin-32 may serve as a biomarker for pulmonary arterial hypertension (PAH) in scleroderma patients, for whom PAH is a severe complication. The study reporting the findings, “Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension,” was published in the journal …
Liquidia Technologies, a company developing an inhaled form of treprostinil for pulmonary arterial hypertension (PAH), has established an agreement to acquire the rare disease company and marketer of generic treprostinil injections, RareGen, strengthening the company’s efforts in the PAH field. Under the agreement, the two companies will…
U.S. veterans with pulmonary hypertension (PH) due to left heart disease and chronic lung disease are more likely to be inappropriately prescribed phosphodiesterase-5 inhibitors (PDE5i) if they have received care both in and out of the Veterans Health Administration (VA), a study has found. Other factors for…
Uptravi (selexipag), an approved oral therapy for adults with pulmonary arterial hypertension (PAH), appears to also be safe and effective as an add-on treatment for children and adolescents, improving several relevant markers of the disease, a small study found. Its researchers recommended larger…
The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease in the United States. People with rare diseases know that the impacts of such conditions extend beyond just medical…
Get regular updates to your inbox.